Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

Partnership leverages BioHorizons' commercial network to broaden availability of Xtant's allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™

BELGRADE, Mont., Aug. 27, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced an exclusive partnership with BioHorizons (a Henry Schein, Inc. company), whereby BioHorizons will distribute Xtant's allogeneic growth factor technology under the private brand Prolifica™ through its commercial network.

The agreement establishes BioHorizons as the exclusive distributor of Xtant's allogeneic growth factor technology into the dental and oral-maxillofacial procedure markets in the United States and Canada, expanding access to the advanced allograft technology for clinicians served by the BioHorizons commercial organization. The partnership reflects a long-term strategic relationship between the two companies, combining Xtant's regenerative medicine development and manufacturing capabilities with BioHorizons' established commercial reach and customer relationships. Both companies expect the collaboration to create a durable channel for expanding access to Prolifica™ and to serve as a foundation for continued collaboration between the organizations.

Sean Browne, President and CEO of Xtant Medical, stated, "This exclusive partnership brings together Xtant's expertise in regenerative biologics with BioHorizons' trusted commercial organization, positioning both companies to deliver meaningful value to clinicians and the patients they serve. We look forward to a productive, long-standing collaboration."

Steve Boggan, President and CEO of BioHorizons, stated, "Prolifica™ is a strong complement to our regenerative portfolio, and this partnership allows us to bring advanced allogeneic growth factors to more of the clinicians who rely on us. We look forward to a long-term collaboration that benefits both organizations and, most importantly, the patients we collectively serve."

Prolifica™ is a naturally occurring blend of allogeneic growth factors, stabilized by native human collagen and delivered in their intrinsic structure, concentration, and composition. Processed to preserve the natural biphasic release of proteins, this advanced allograft supports bone healing and regeneration across a range of clinical applications.

Prolifica™ is now accessible to clinicians through BioHorizons' commercial network.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that contain words such as "intends," "expects," "anticipates," "plans," "believes," "estimates," "continue," "future," "will," "potential," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the benefits, strategic value, and duration of its partnership with BioHorizons; the anticipated expansion of access to Prolifica™ through BioHorizons' commercial network; and the expected performance of Prolifica™. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of the Company and BioHorizons to perform their respective obligations under, and realize the anticipated benefits of, the partnership; the possibility that the arrangement may be terminated or modified; the ability of Prolifica™ to gain market acceptance, perform as designed and intended, and meet the needs of clinicians and patients; the Company's ability to successfully manufacture Prolifica™ in amounts required to meet demand; the performance and success of the Company's fully vertically integrated structure; the Company's ability to continue to innovate, develop and introduce new products and the success of those products; the Company's future operating and financial performance and its ability to increase or maintain revenue; and other risk factors contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 31, 2026 and subsequent SEC filings by the Company. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.